DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/07fbd3/generic_growth_str) has announced the addition of the "Generic Growth ...
Risk evaluation and mitigation strategy (REMS) programs help ensure that the benefits of certain high-risk medications outweigh their risks. With the routine use of REMS programs, however, concerns ...
Patent expiry across API, formulation, and device IP is expected to catalyze biosimilar competition, expanding access while compressing pricing across pharmaceutical and device value chains.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results